

## **T cell tuning molecules that modify the immune response to cancer cells**

### **Summary**

Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seek partners to collaborate on *in vitro* studies to validate these potential immunomodulators and to conduct *in vivo* studies in a murine cancer model to determine the effects of ligands (e.g., antibodies) to the proteins on the immune response to cancer cells. Preference will be given to responses received by March 31, 2016.

### **NIH Reference Number**

E-117-2016

### **Product Type**

- Therapeutics

### **Collaboration Opportunity**

This invention is available for licensing and co-development.

### **Contact**

- Richard Girards  
NCI TTC

[richard.girards@nih.gov](mailto:richard.girards@nih.gov) (link sends e-mail)

### **Description of Technology**

Researchers at NIH/NICHD have identified approximately 200 proteins as candidate molecules (leads) that “fine tune” T cell receptor (TCR) signaling. *Eunice Kennedy Shriver National Institute of Child Health and Human Development* (NICHD) seeks partners to collaborate on *in vitro* studies to validate these potential immunomodulators and to conduct *in vivo* studies in a murine cancer model to determine the effects of ligands (e.g. antibodies) to the proteins to determine their effect on the immune response to cancer cells. Preference will be given to responses received by March 31, 2016.

### **Potential Commercial Applications**

Agents that modify the immune response to cancer cells could be used in conjunction with other immunomodulators or therapeutic agents, such as vaccines

### **Inventor(s)**

[Paul Love \(NICHD\)](#), [J. Pinkhasov \(NICHD\)](#), [Z. Li \(NICHD\)](#)

## **Development Stage**

- Discovery (Lead Identification)

## **Publications**

Pending

## **Patent Status**

- **Research Material:** NIH will not pursue patent prosecution for this technology

## **Therapeutic Area**

- Cancer/Neoplasm

## **Updated**

Thursday, April 13, 2023

**Source URL:** <https://techtransfer.cancer.gov/availabletechnologies/e-117-2016>